Popular Articles

Arena Pharmaceuticals Announces The Presentation Of Lorcaserin Phase 3 BLOOM Data At The American Diabetes Association's 69th Scientific Sessions
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) trial has been accepted for a poster presentation at the American Diabetes Association"s 69th Scientific Sessions in New Orleans, Louisiana. The abstract, titled "Lorcaserin Reduces Body Weight in Obese and Overweight Subjects: Behavioral Modification and Lorcaserin for Overweight and Obesity Management, the BLOOM Trial," will be displayed from June 6, 2009 at 10:00 a.m. Central Daylight Time (CDT) until June 8, 2009 at 4:00 p.m. CDT in the Morial Convention Center, Hall E. The poster has been assigned presentation number 96-LB in category 20-B Obesity - Clinical Treatment.
generic viagra online
Aetna Pilot Helps Physicians Improve Care For Diabetics
Aetna (NYSE: AET) and Total Therapeutic Management (TTM) announced the results of a pilot program in Southeastern Pennsylvania and South Florida that improved patient care and increased the number of physicians recognized by the National Committee for Quality Assurance (NCQA) Diabetes Physician Recognition Program. Funded by Amylin Pharmaceuticals, Inc., the program included outreach to physicians, chart reviews, and face-to-face meetings to discuss appropriate screening tests and gauge how patient care was being managed. Of the 40 physicians who participated in the 2008 pilot, 17 were recognized by the NCQA for providing high-quality care to patients with diabetes. Findings from the program were presented at the ISPOR international meeting held in Orlando, Florida.
News of the day
Plans To Improve Access To Occupational Health Services In Wales Announced
Plans to improve access to occupational health services in Wales to help tackle absenteeism and ill-health in the workplace will be announced today [Tuesday, 14 July] by Health Minister Edwina Hart.
Public Health

LSUHSC Dental Researcher Funded To Develop Better Dental Materials

Xiaoming, Xu, PhD, Associate Professor and Director of Biomaterials Research at LSU Health Sciences Center New Orleans School of Dentistry, has been awarded a grant in the amount of $1.77 million over four years by the National Institutes of Health to develop new antibacterial, fluoride-releasing, and bioactive dental materials including dental composites, bonding agents, and sealants. Currently most dental fillings and cosmetic restorations, including bonding and veneers, are done with resin-based dental composites - tooth-colored, plastic, and glass materials. Dr. Xu is working to develop the next generation of dental materials designed to reduce the secondary cavities that often develop around dental resin-based composite fillings as they shrink, causing them to fail. The new materials are expected to reduce secondary cavities and to prolong the life of restorations. According to the National Institute of Dental and Craniofacial Research, tooth decay remains the most prevalent chronic disease in both children and adults, even though it is largely preventable. For the latest reporting period (1999-2004), the percentage of people who have had cavities in their permanent teeth are 92% of adults 20 to 64, 59% of adolescents 12 to 19, and 92% of seniors 65 and older. Forty-two percent of children 2 to 11 have had cavities in their primary teeth. "The development of these materials has the potential to make a huge impact on oral health care and oral health quality of life, in particular for the vast number of people at high risk for cavities - children, the elderly, those medically compromised who suffer from xerostomia or dry mouth, and those with mental or physical challenges," notes Dr. Xu. Leslie Capo Louisiana State University Health Sciences Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):